Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Pancreatic and Gastrointestinal Tumor Registry and Tissue Collection (SPORE)

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2014 by University of Alabama at Birmingham
Sponsor:
Collaborator:
Information provided by (Responsible Party):
University of Alabama at Birmingham
ClinicalTrials.gov Identifier:
NCT00584363
First received: December 24, 2007
Last updated: June 1, 2014
Last verified: June 2014
  Purpose

The purpose of the study is to collect pancreatic tissue, blood and urine from adults to study pancreatic abnormalities.


Condition
Pancreatic Cancer

Study Type: Observational
Study Design: Time Perspective: Cross-Sectional
Official Title: Pancreatic and Gastrointestinal Tumor Registry and Tissue Collection (UAB/UMN SPORE in Pancreatic Cancer)

Resource links provided by NLM:


Further study details as provided by University of Alabama at Birmingham:

Primary Outcome Measures:
  • To diagnose Pancreatic Cancer [ Time Frame: 5 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Preventing patient form being misdiagnosed [ Time Frame: 5 years ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

Specimens are frozen and stored


Estimated Enrollment: 600
Study Start Date: June 2004
Estimated Study Completion Date: June 2015
Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Detailed Description:

The aim of the study is to standardize, collect and share pancreatic cancer related information, to be used for research purposes only by researchers from different participating institutions/centers.

  Eligibility

Ages Eligible for Study:   19 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Adults 19 years of age or older, pancreatic cancer patients at the University of Alabam at Birmingham.

Criteria

Inclusion Criteria:

  • Person over 19 years of age, patient with a tissue-proven diagnosis of pancreatic cancer at the University of Alabama at Birmingham (UAB) University Hospital during the period, and cognitive ability to provide informed consent

Exclusion Criteria:

  • Person not 19 or older and have not had a tissue-proven diagnosis of pancreatic cancer.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00584363

Contacts
Contact: Stacey Branham, RN, BSN (205) 975-9564 sbranham@uab.edu
Contact: Toni Seay, M.A. (205) 934-7332 tamartin@uab.edu

Locations
United States, Alabama
University of Alabama at Birmingham Recruiting
Birmingham, Alabama, United States, 35294
Sponsors and Collaborators
University of Alabama at Birmingham
Investigators
Principal Investigator: Charles M Wilcox, MD University of Alabama at Birmingham
  More Information

No publications provided

Responsible Party: University of Alabama at Birmingham
ClinicalTrials.gov Identifier: NCT00584363     History of Changes
Other Study ID Numbers: F040514008, #000185970, 2P50CA101955
Study First Received: December 24, 2007
Last Updated: June 1, 2014
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Digestive System Neoplasms
Gastrointestinal Neoplasms
Pancreatic Neoplasms
Digestive System Diseases
Endocrine Gland Neoplasms
Endocrine System Diseases
Gastrointestinal Diseases
Neoplasms
Neoplasms by Site
Pancreatic Diseases

ClinicalTrials.gov processed this record on November 27, 2014